| Unique ID issued by UMIN | UMIN000006273 |
|---|---|
| Receipt number | R000007427 |
| Scientific Title | A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation |
| Date of disclosure of the study information | 2011/09/02 |
| Last modified on | 2014/09/02 12:49:19 |
A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation
A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation
A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation
A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation
| Japan |
Non-Small Cell Lung Cancer
| Pneumology |
Malignancy
NO
To determine the maximum tolerated dose (MTD) of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation
Safety,Efficacy
Exploratory
Phase I
Maximum tolerated dose (MTD) of pemetrexed and gefitinib
Anti tumor efficacy
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
| Medicine |
Level 1 gefitinib250mg/day and pemetrexed (300mg/m2)
Level 2 gefitinib250mg/day and pemetrexed (400mg/m2)
Level 3 gefitinib250mg/day and pemetrexed (500mg/m2)
If none of the 3 patients who had been originally allocated to a dosage level experienced
DLT, the dose of pemetrexed was increased to the next level. If one of the 3 patients experienced DLT at that level, 3 additional patients were enrolled for the further evaluation of toxicity. If two of 3 patients experienced DLT at that level, that dose was defined as the MTD.
| 70 | years-old | <= |
| Not applicable |
Male and Female
1)Histology/cytology-proven non-small cell lung cancer, age of 70 years or over
2)NSCLC harboring mutations of EGFR
3)Stage IIIB, IV
4)Chemotherapy naïve patients
5)Performance status(ECOG): 0-1
6)Adequate organ function
7)Written informed consent
1)Serious infections
2)Serious clinical problems
3)Interstitial pneumonia/lung fibrosis on chest CT
4)Active concomitant malignancy
5)Symptomatic brain metastasis
6)Massive pericardial, pleural effusion, ascites
7)Previous drug allergy
8)Those judged to be not suitable by the attending physician
11
| 1st name | |
| Middle name | |
| Last name | Masao Ichiki |
National Hospital Organization Kyushu Medical Center
Department of Respiratory Medicine
1-8-1 Jigyohama Chuo-ku, Fukuoka 810-8563, Japan
092-852-0700
ichiki@kyumed.jp
| 1st name | |
| Middle name | |
| Last name | Masao Ichiki |
National Hospital Organization Kyushu Medical Center
Department of Respiratory Medicine
1-8-1 Jigyohama Chuo-ku, Fukuoka 810-8563, Japan
092-852-0700
ichiki@kyumed.jp
National Hospital Organization Kyushu Medical Center
Department of Respiratory Medicine
National Hospital Organization Kyushu Medical Center
Department of Respiratory Medicine
Other
NO
| 2011 | Year | 09 | Month | 02 | Day |
Unpublished
Completed
| 2010 | Year | 09 | Month | 27 | Day |
| 2011 | Year | 09 | Month | 01 | Day |
| 2015 | Year | 03 | Month | 30 | Day |
| 2015 | Year | 09 | Month | 02 | Day |
| 2015 | Year | 03 | Month | 30 | Day |
| 2011 | Year | 09 | Month | 02 | Day |
| 2014 | Year | 09 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007427